Cowden syndrome-affected patients with PTEN promoter mutations demonstrate abnormal protein translation

American Journal of Human Genetics

Volumn 81, Issue 4, 2007, Pages 756-767

  Teresi, Rosemary E ^a   Zbuk, Kevin M ^a   Pezzolesi, Marcus G ^a   Waite, Kristin A ^a,b   Eng, Charis ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

5' UNTRANSLATED REGION; ARTICLE; BREAST CANCER; CONTROLLED STUDY; COWDEN SYNDROME; DIAGNOSTIC PROCEDURE; DISEASE COURSE; ENDOMETRIUM CANCER; ENZYME ACTIVITY; GENE MUTATION; GENE STRUCTURE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; PHOSPHATASE AND TENSIN HOMOLOG DELETED ON CHROMOSOME 10 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN BINDING; THYROID CANCER; TUMOR SUPPRESSOR GENE;

EID: 35348964057     PISSN: 00029297     EISSN: None     Source Type: Journal    
DOI: 10.1086/521051     Document Type: Article

References (48)

1. Alibaba, http://www.gene-regulation.com/pub/programs/alibaba2/index.html
2. Genomic Medicine Biorepository of the Cleveland Clinic Genomic Medicine Institute, http://www.lerner.ccf.org/gmi/gmb/methods.php
3. MFOLD, http://bioweb.pasteur.fr/seqanal/interfaces/mfold-simple.html
4. National Comprehensive Cancer Network, http://www.nccn.org/
5. Online Mendelian Inheritance in Man (OMIM), http://www.ncbi.nlm.nih.gov/ Omim/ (for CS, BRRS, and Proteus syndrome)
6. TESS, http://www.cbil.upenn.edu/cgi-bin/tess/tess
7. TFSEARCH, http://www.cbrc.jp/research/db/TFSEARCH.html
8. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, et al (1997) Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16:64-67
9. Marsh DJ, Kum JB, Lunetta KL, Bennett MJ, Gorlin RJ, Ahmed SF, Bodurtha J, Crowe C, Curtis MA, Dasouki M, et al (1999) PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 8:1461-1472
10. Zhou XP, Waite KA, Pilarski R, Hampel H, Fernandez MJ, Bos C, Dasouki M, Feldman GL, Greenberg LA, Ivanovich J, et al (2003) Germline PTEN promoter mutations and deletions in Cowden/Bannayan-Riley-Ruvalcaba syndrome result in aberrant PTEN protein and dysregulation of the phosphoinositol-3- kinase/Akt pathway. Am J Hum Genet 73:404-411
11. Witman PM (2006) More than just a bump: the hamartoma syndromes. Adv Dermatol 22:157-180
12. Zbuk KM, Eng C (2007) Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 7:35-45
13. Eng C (2003) PTEN: one gene, many syndromes. Hum Mutat 22:183-198
14. Ries LAG, Eigne EM, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Fay MP, Feuer EJ, Edwards BK (2003) SEER cancer statistics review, 1975-2000. National Cancer Institute, Bethesda, MD
15. Pilarski R, Eng C (2004) Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet 41:323-326
16. Gorlin RJ, Cohen MM Jr, Condon LM, Burke BA (1992) Bannayan-Riley- Ruvalcaba syndrome. Am J Med Genet 44:307-314
17. Butler MG, Dasouki MJ, Zhou XP, Talebizadeh Z, Brown M, Takahashi TN, Miles JH, Wang CH, Stratton R, Pilarski R, et al (2005) Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 42: 318-321
18. Eng C (2000) Will the real Cowden syndrome please stand up: revised diagnostic criteria. J Med Genet 37:828-830
19. Pezzolesi MG, Zbuk KM, Waite KA, Eng C (2007) Comparative genomic and functional analyses reveal a novel cis-acting PTEN regulatory element as a highly conserved functional E-box motif deleted in Cowden syndrome. Hum Mol Genet 16: 1058-1071
20. Tang Y, Eng C (2006) p53 Down-regulates phosphatase and tensin homologue deleted on chromosome 10 protein stability partially through caspase-mediated degradation in cells with proteasome dysfunction. Cancer Res 66:6139-6148
21. Pezzolesi MG, Li Y, Zhou XP, Pilarski R, Shen L, Eng C (2006) Mutation-positive and mutation-negative patients with Cowden and Bannayan-Riley-Ruvalcaba syndromes associated with distinct 10q haplotypes. Am J Hum Genet 79:923-934
22. Hettinger K, Vikhanskaya F, Poh MK, Lee MK, de Belle I, Zhang JT, Reddy SA, Sabapathy K (2007) c-Jun promotes cellular survival by suppression of PTEN. Cell Death Differ 14: 218-229
23. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685
24. Sarquis MS, Agrawal S, Shen L, Pilarski R, Zhou XP, Eng C (2006) Distinct expression profiles for PTEN transcript and its splice variants in Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am J Hum Genet 79:23-30
25. Sheng X, Koul D, Liu JL, Liu TJ, Yung WK (2002) Promoter analysis of tumor suppressor gene PTEN: identification of minimum promoter region. Biochem Biophys Res Commun 292:422-426
26. Han B, Dong Z, Liu Y, Chen Q, Hashimoto K, Zhang JT (2003) Regulation of constitutive expression of mouse PTEN by the 5′-untranslated region. Oncogene 22:5325-5337
27. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, Mak TW (2001) Regulation of PTEN transcription by p53. Mol Cell 8:317-325
28. Vasudevan KM, Gurumurthy S, Rangnekar VM (2004) Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol 24:1007-1021
29. Zuker M (1989) On finding all suboptimal foldings of an RNA molecule. Science 244:48-52
30. Jiang Y, Saavedra HI, Holloway MP, Leone G, Altura RA (2004) Aberrant regulation of survivin by the RB/E2F family of proteins. J Biol Chem 279:40511-40520
31. Virolle T, Adamson ED, Baron V, Birle D, Mercola D, Mustelin T, de Belle I (2001) The Egr-1 transcription factor directly activates PTEN during irradiation-induced signalling. Nat Cell Biol 3:1124-1128
32. Whelan JT, Forbes SL, Bertrand FE (2007) CBF-1 (RBP-Jkappa) binds to the PTEN promoter and regulates PTEN gene expression. Cell Cycle 6:80-84
33. Bonofiglio D, Gabriele S, Aquila S, Catalano S, Gentile M, Middea E, Giordano F, Ando S (2005) Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells. Clin Cancer Res 11:6139-6147
34. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH (2001) Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 11:764-768
35. Teresi RE, Shaiu CW, Chen CS, Chatterjee VK, Waite KA, Eng C (2006) Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Int J Cancer 118:2390-2398
36. Schung J, Overton GC (1997) Technical report CBIL-TR-1997-1001-v0.0. School of Medicine, University of Pennsylvania, Philadelphia
37. Grabe N (2002) AliBaba2: context specific identification of transcription factor binding sites. In Silico Biol 2:S1-S15
38. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, Kel OV, Ignatieva EV, Ananko EA, Podkolodnaya OA, Kolpakov FA, et al (1998) Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26: 362-367
39. Williams K, Fernandez S, Stien X, Ishii K, Love HD, Lau YF, Roberts RL, Hayward SW (2005) Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate 63:369-384
40. Signori E, Bagni C, Papa S, Primerano B, Rinaldi M, Amaldi F, Fazio VM(2001) A somatic mutation in the 5′UTR of BRCA1 gene in sporadic breast cancer causes down-modulation of translation efficiency. Oncogene 20:4596-4600
41. Kozak M (1986) Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44:283-292
42. Mignone F, Gissi C, Liuni S, Pesole G (2002) Untranslated regions of mRNAs. Genome Biol 3:REVIEWS0004
43. Saxena A, de Lagarde D, Leonard H, Williamson SL, Vasudevan V, Christodoulou J, Thompson E, MacLeod P, Ravine D (2006) Lost in translation: translational interference from a recurrent mutation in exon 1 of MECP2. J Med Genet 43: 470-477
44. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528
45. Komar AA (2007) Genetics: SNPs, silent but not invisible. Science 315:466-467
46. Nackley AG, Shabalina SA, Tchivileva IE, Satterfield K, Korchynskyi O, Makarov SS, Maixner W, Diatchenko L (2006) Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 314:1930-1933
47. Svitkin YV, Pause A, Haghighat A, Pyronnet S, Witherell G, Belsham GJ, Sonenberg N (2001) The requirement for eukaryotic initiation factor 4A (elF4A) in translation is in direct proportion to the degree of mRNA 5′ secondary structure. RNA 7:382-394
48. Chung JH, Eng C (2005) Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res 65:8096-8100